EP1503739A4 - Sustained release of guaifenesin combination drugs - Google Patents

Sustained release of guaifenesin combination drugs

Info

Publication number
EP1503739A4
EP1503739A4 EP03736462A EP03736462A EP1503739A4 EP 1503739 A4 EP1503739 A4 EP 1503739A4 EP 03736462 A EP03736462 A EP 03736462A EP 03736462 A EP03736462 A EP 03736462A EP 1503739 A4 EP1503739 A4 EP 1503739A4
Authority
EP
European Patent Office
Prior art keywords
sustained release
combination drugs
guaifenesin
guaifenesin combination
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03736462A
Other languages
German (de)
French (fr)
Other versions
EP1503739A1 (en
Inventor
Robert D Davis
Ralph W Blume
Donald Jeffrey Keyser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser LLC
Original Assignee
Adams Respiratory Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Application filed by Adams Respiratory Therapeutics Inc filed Critical Adams Respiratory Therapeutics Inc
Publication of EP1503739A1 publication Critical patent/EP1503739A1/en
Publication of EP1503739A4 publication Critical patent/EP1503739A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03736462A 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs Ceased EP1503739A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US121706 2002-04-15
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin
US406557 2003-04-04
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs
US406574 2003-04-04
PCT/US2003/011500 WO2003088952A1 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Publications (2)

Publication Number Publication Date
EP1503739A1 EP1503739A1 (en) 2005-02-09
EP1503739A4 true EP1503739A4 (en) 2006-06-21

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03736462A Ceased EP1503739A4 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Country Status (10)

Country Link
EP (1) EP1503739A4 (en)
JP (1) JP5466346B2 (en)
CN (1) CN1655766B (en)
AU (1) AU2003237807B2 (en)
CA (1) CA2481739C (en)
EA (1) EA007156B1 (en)
IL (1) IL164438A0 (en)
MX (1) MXPA04010225A (en)
WO (1) WO2003088952A1 (en)
ZA (1) ZA200409171B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
KR20060076319A (en) * 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 Therapeutic regimens for administering drug combinations
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
EA201001083A1 (en) * 2004-08-13 2011-08-30 Бёрингер Ингельхайм Интернациональ Гмбх COMPOSITION OF TABLET OF PROLONGED SURVIVING, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS MANUFACTURE AND ITS APPLICATION
LT2474545T (en) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CN1994285B (en) * 2006-01-04 2011-03-16 上海医药工业研究院 Sustained release micro-pellet of guaifenesin and preparation process thereof
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (en) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation
DK2394648T3 (en) 2009-02-04 2016-09-26 Astellas Pharma Inc A pharmaceutical composition for oral administration
KR20220015492A (en) 2010-03-10 2022-02-08 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102755304A (en) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 Preparation method of guaifenesin and dextromethorphan hydrobromide capsules
PE20200175A1 (en) 2012-11-15 2020-01-24 Incyte Holdings Corp SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS
CA3155500A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CN105982860B (en) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 Guaifenesin water-free swallowable taste-masking granule
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO2000033818A1 (en) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4552899B1 (en) * 1984-04-09 1992-10-20 Analgesic Associates
EP0384514A2 (en) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
WO2000033818A1 (en) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03088952A1 *

Also Published As

Publication number Publication date
EA200401369A1 (en) 2005-06-30
IL164438A0 (en) 2005-12-18
AU2003237807A1 (en) 2003-11-03
ZA200409171B (en) 2005-07-27
CA2481739A1 (en) 2003-10-30
WO2003088952A1 (en) 2003-10-30
JP5466346B2 (en) 2014-04-09
CA2481739C (en) 2012-10-02
EP1503739A1 (en) 2005-02-09
MXPA04010225A (en) 2005-07-05
JP2005528402A (en) 2005-09-22
CN1655766B (en) 2012-05-30
AU2003237807B2 (en) 2008-10-23
EA007156B1 (en) 2006-08-25
CN1655766A (en) 2005-08-17

Similar Documents

Publication Publication Date Title
IL236190A0 (en) Sustained release of antiinfectives
EP1537880A4 (en) Sustained release preparation
EP1503739A4 (en) Sustained release of guaifenesin combination drugs
EP1549296A4 (en) Sustained release formulations of metformin
IL166424A0 (en) Sustained release formulations comprising lamotigine
IL173866A0 (en) Sustained release dosage forms of ziprasidone
EP1581236A3 (en) Sustained release of antiinfectives
HK1107672A1 (en) Conveniently implantable sustained release drug compositions
HK1084043A1 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AU2003260803A8 (en) Sustained release pharmaceutical composition
IL176222A0 (en) Sustained release torsemide dosage forms
TWI319318B (en) Modified release pharmaceutical formulation
EP1564220A4 (en) Sustained release drug carrier
EP1802346A4 (en) Sustained release pharmaceutical composition
EP1411904A4 (en) Sustained release pharmaceutical composition
PL376840A1 (en) Prolonged release pharmaceutical composition
GB0202900D0 (en) Novel formulations of drugs
EP1478353A4 (en) Sustained release pharmaceutical composition
GB0119848D0 (en) Delayed and sustained drug release
EP1483580A4 (en) Biomarker for efficacy of appetite suppressant drugs
IL176061A0 (en) Nitrooxyderivatives of antihypertensive drugs
EP1501844A4 (en) Disaccharides for drug discovery
EP1652522A4 (en) Sustained release tablet for oral use
GB0327742D0 (en) Novel uses of known drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072906

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADAMS RESPIRATORY THERAPEUTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20060523

17Q First examination report despatched

Effective date: 20071031

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RECKITT, BENCKISER, INC.

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RECKITT BENCKISER LLC

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1072906

Country of ref document: HK

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150126